Epidermal Growth Factor Receptor (EGFR) Signaling Regulates Global Metabolic Pathways in EGFR-mutated Lung Adenocarcinoma

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer

(2013) Makoto Sudo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Nuclear PKM2 regulates the Warburg effect

(2013) Weiwei Yang et al.   CELL CYCLE

EGFR Mutation-Induced Alternative Splicing of Max Contributes to Growth of Glycolytic Tumors in Brain Cancer

(2013) Ivan Babic et al.   Cell Metabolism

Glycolysis Inhibition Sensitizes Non-Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation

(2013) S. M. Kim et al.   MOLECULAR CANCER THERAPEUTICS

AMPK-Dependent Degradation of TXNIP upon Energy Stress Leads to Enhanced Glucose Uptake via GLUT1

(2013) Ning Wu et al.   MOLECULAR CELL

Post-translational modifications and the Warburg effect

(2013) T Hitosugi et al.   ONCOGENE

Identification and Characterization of Cancer Mutations in Japanese Lung Adenocarcinoma without Sequencing of Normal Tissue Counterparts

(2013) Ayako Suzuki et al.   PLoS One

Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1

(2013) I. Ben-Sahra et al.   SCIENCE

Tumour-associated mutant p53 drives the Warburg effect

(2013) Cen Zhang et al.   Nature Communications

Regulation of Glucose Transporter Translocation in Health and Diabetes

(2012) Jonathan S. Bogan   Annual Review of Biochemistry

Tyrosine Kinase Inhibitors: Views of Selectivity, Sensitivity, and Clinical Performance

(2012) Alexander Levitzki   Annual Review of Pharmacology and Toxicology

Cancer metabolism: Key players in metabolic reprogramming

(2012) Tomoyoshi Soga   CANCER SCIENCE

Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

(2012) Marcin Imielinski et al.   CELL

Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism

(2012) Haoqiang Ying et al.   CELL

c-Myc and Cancer Metabolism

(2012) D. M. Miller et al.   CLINICAL CANCER RESEARCH

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

(2012) Vincent A Miller et al.   LANCET ONCOLOGY

Metabolomic profiling of lung and prostate tumor tissues by capillary electrophoresis time-of-flight mass spectrometry

(2012) Kenjiro Kami et al.   Metabolomics

Therapeutic targets in cancer cell metabolism and autophagy

(2012) Heesun Cheong et al.   NATURE BIOTECHNOLOGY

Aerobic Glycolysis: Meeting the Metabolic Requirements of Cell Proliferation

(2011) Sophia Y. Lunt et al.   Annual Review of Cell and Developmental Biology

EGFR Mutations and Lung Cancer

(2011) Gilda da Cunha Santos et al.   Annual Review of Pathology-Mechanisms of Disease

The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry

(2011) Fionnuala Morrish et al.   CELL CYCLE

Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer

(2011) I. S. Donev et al.   CLINICAL CANCER RESEARCH

Early [18F]Fluorodeoxyglucose Positron Emission Tomography at Two Days of Gefitinib Treatment Predicts Clinical Outcome in Patients with Adenocarcinoma of the Lung

(2011) R. Takahashi et al.   CLINICAL CANCER RESEARCH

Role of Survivin in EGFR Inhibitor-Induced Apoptosis in Non-Small Cell Lung Cancers Positive for EGFR Mutations

(2010) K. Okamoto et al.   CANCER RESEARCH

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes

(2010) A. J. Levine et al.   SCIENCE

Clinical Applications of Metabolomics in Oncology: A Review

(2009) J. L. Spratlin et al.   CLINICAL CANCER RESEARCH

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

(2009) Wenjun Zhou et al.   NATURE

HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer

(2009) Charles J. David et al.   NATURE

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC

(2009) Helena Linardou et al.   Nature Reviews Clinical Oncology

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

(2009) M. G. Vander Heiden et al.   SCIENCE

Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth

(2009) T. Hitosugi et al.   Science Signaling

Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity

(2008) Zhang Weihua et al.   CANCER CELL